Researchers in Hong Kong planned a clinical trial to test whether long-acting injectable antipsychotic medications could help people who have both substance use disorders and psychosis. The study aimed to compare two medications, aripiprazole and paliperidone, against standard treatment in 165 participants with conditions like stimulant-induced psychotic disorder or schizophrenia. The trial record explains the study's design and rationale, describing it as an early intervention strategy.
This source is a trial registration, not a results publication. It tells us what the researchers intended to study, but it does not contain any data on what actually happened. We do not know if the medications were effective at managing psychosis in this group, or if participants experienced any side effects. The record shows the study's primary completion date was May 2024, but no outcomes are shared here.
Because no results are reported, we cannot draw any conclusions about this treatment approach. Readers should understand that this document only shows a plan for research. It does not provide evidence that the injections work for this specific purpose. The findings, when they become available in future publications, will need careful evaluation to understand their real-world meaning for patients.